Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Attibute
Boston, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Attribute Therapeutics is a biotechnology company focused on developing novel small molecule therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). The company's lead program targets the Dual Leucine Zipper Kinase (DLK), also known as MAP3K12, a key regulator of neuronal stress responses and axonal degeneration. By inhibiting DLK, Attribute aims to preserve neuronal function and slow disease progression in patients with devastating neurological conditions. The company was founded by industry veterans with significant experience in neuroscience drug discovery and development.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Attibute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Attibute.